Ranibizumab w leczeniu cukrzycowego obrzęku plamki

• Authors: Anna Bryl , Małgorzata Mrugacz

Title variants

EN

Ranibizumab in the treatment of diabetic macular edema

• Languages of publication: PL

Abstracts

PL

Cukrzyca jest chorobą stanowiącą duży problem społeczny. Badania epidemiologiczne dotyczące zapadalności na cukrzycę typu 1 i 2 na świecie wykazują ciągły wzrost liczby zachorowań. Wraz ze wzrostem czasu trwania cukrzycy wzrasta prawdopodobieństwo znacznych zmian naczyniowych siatkówki i rozwoju obrzęku plamki. Zastosowanie ranibizumabu w iniekcji doszklistkowej zrewolucjonizowało leczenie powikłań ocznych cukrzycy. Lek ten stosowany jest w ramach leczenia pierwszego rzutu w przypadku klinicznie znamiennego obrzęku plamki z zajęciem dołka i pogorszeniem ostrości wzroku. W licznych badaniach wykazano większą skuteczność jego leczenia ranibizumabem – zarówno w monoteraii, jak i w skojarzeniu z laseroterapią – w porównaniu z laseroterapią, która do niedawna jeszcze była złotym standardem leczenia.

EN

Diabetes is an important social problem. Epidemiological studies show a worldwide increase in the incidence of type 1 and 2 diabetes. Increasing duration of diabetes significantly raises the risk of the retinal vascular changes and the development of the macular edema. Ranibizumab in intravitreal injection has revolutionized the treatment of ocular complications of diabetes. It is used as part of the first-line treatment for clinically significant macular edema with occlusion and worsening of visual acuity. Numerous studies have demonstrated greater efficacy of the treatment with ranibizumab (both in monotherapy and in combination with laser therapy) compared to laser therapy, which was the gold standard of therapy.

Keywords

EN

cukrzyca; leczenie anty-VEGF; obrzęk plamki; retinopatia cukrzycowa

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2019
• Volume: 6
• Issue: 2
• Pages: 105-109

Contributors

author

Anna Bryl

• Samodzielna Pracownia Rehabilitacji Narządu Wzroku, Uniwersytet Medyczny w Białymstoku

author

Małgorzata Mrugacz

• Samodzielna Pracownia Rehabilitacji Narządu Wzroku, Uniwersytet Medyczny w Białymstoku

References

• 1. Beyloe JP, Honeycutt AA, Narayan KM, et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 2001; 24(11): 1936-1940.
• 2. Amos AF, McCarty DJ, Zimmet P. The rising global burden of diabetes and complications: estimates and projections to the year 2010. Diabet Med 1997; 14(5): 1-5.
• 3. Chojnowski P, Wasyluk J, Grabska-Liberek I. Cukrzyca – epidemiologia i patogeneza. Postępy Nauk Medycznych 2009; 6: 420-428.
• 4. Foulds WS, MacCuish ATB. Diabetic retinopathy in the west of Scotland: its detection and prevalence, and the cost-effectiveness of a proposed screening programme. Health Bulletin 1983; 41(6): 318-326.
• 5. Prevention of blindness from diabetes mellitus. Report of WHO consultation in Geneva, Switzerland, 9-11 November 2005.
• 6. Wild S, Roglic G, Green A, et al. Global Prevalance of Diabetes. Estimates for the year 2000 and projections for 2030. Diab Care 2004; 27(5): 1047-1053.
• 7. Guariguata L. By the numbers: new estimates from the IDF Diabetes Atlas Update for 2012. Diabetes Res Clin Pract 2012; 98: 524-525. DOI: 10.1016/j.diabres.2012.11.006.
• 8. Resnikoff S, Pascolini D, Etya‘ale D, et al. Global Data on Visual impairment in the year 2002. Bulletin of the World Health Organization 2004; 82: 844-851.
• 9. Kempen JH, O’Colmain BJ, Leske MC, et al. The prevalence of diabetic retinopathy among adults in the United States. Arch Ophthalmol 2004; 122(4): 552-563.
• 10. Roy MS, Klein R, O‘Colmain BJ, et al. The prevalence of diabetic retinopathy among adult type 1 diabetic persons in the United States. Arch Ophthalmol 2004; 122: 546-551.
• 11. Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care 2012; 35: 556-564.
• 12. Shin ES, Sorenson CM, Sheibani N. Diabetes and retinal vascular dysfunction. J Ophthalmic Vis Res 2014; 9(3): 362-373. DOI: 10.4103/2008-322X.143378.
• 13. Regillo CD. Retina and vitreous. Basic and Clinical Science Course. Section 12, 2005-2006. American Academy of Ophthalmology.
• 14. Arden GB, Sidman RL, Arap W, et al. Spare the rod and spoil the eye. Br J Ophthalmol 2005; 89: 764-769.
• 15. Simó R, Hernández C. European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR). Neurodegeneration is an early event in diabetic retinopathy: therapeutic implications. Br J Ophthalmol 2012; 96(10): 1285-1290.
• 16. Marczak M. Zastosowanie ranibizumabu w leczeniu cukrzycowego obrzęku plamki w materiale własnym. OphthaTherapy 2014; 1(3): 165-169.
• 17. Moss SE, Klein R, Klein BE. The 14-year incidence of visual loss in a diabetic population. Ophthalmology 1998; 105(6): 998-1003.
• 18. Kur J, Newman EA, Chang-Ling T. Cellular and physiological mechanisms underlying blood flow regulation in the retina choroid in health diseases. Prog Retin Eye Res 2012; 31(5): 377-406.
• 19. Bandello F, Lattanzio R, Zucchiatti I, et al. Pathophysiology and treatment of diabetic retinopathy. Acta Diabetol 2013; 50: 1-20.
• 20. Abbott NJ, Rönnbäck L, Hansson E. Astrocyte-endothelial interactions at the blood-brain barrier. Nat Rev Neurosci 2006; 7: 41-53.
• 21. Klein R, Klein B, Moss S, et al. The Wisconsin epidemiologic study of diabetic retinopathy. XV. The long-term incidence of macula edema. Ophthalmology 1995; 102: 7-16.
• 22. Kański J, Milewski SA. Choroby plamki. WM Górnicki, Wrocław 2003.
• 23. Aiello LP, Avery LR, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994; 331: 1480-1487.
• 24. Browning DJ, Glassman AR, Aiello LP, et al. Diabetic Retinopathy Clinical Research Network: Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 2008; 115(8): 1366-1371.
• 25. Kubicka-Trząska A. Doszklistkowe iniekcje ranibizumabu w leczeniu cukrzycowego obrzęku plamki. Klinika Okulistyczna 2010: 10-12.
• 26. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the macula in Diabetes (READ-2) study. Ophthalmology 2009; 116: 2175-2181.
• 27. Chun DW, Heier JS, Topping TM, et al. A pilot study of multiple intravitreal injections of ranibizumab in patients with cente-rinvolving clinically significant diabetic macular edema. Ophthalmology 2006; 113(10): 1706-1712.
• 28. Vellanki S, Ferrigno A, Alanis Y, et al. High glucose and glucose deprivation modulate müller cell viability and VEGF Secretion. Int J Ophthalmol Eye Sci 2016; 4: 178-183.
• 29. Rejdak R, Ozimek M, Chorągiewicz T, et al. Współczesne możliwości leczenia cukrzycowego obrzęku plamki – wyniki własne. Ophthalmol J 2017; 2(1): 1-7.
• 30. Novartis – monografia produktu leczniczego Lucentis.
• 31. Teper S. Nowe trendy w leczeniu cukrzycowego obrzęku plamki. Przegląd Okulistyczny 2011; 2(40): 9.
• 32. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; RESTORE study group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118(4): 615-625.
• 33. Szilard K. Moving Beyond Laser in treatment DME, BRVO. Retina Today 2012: 48-50.
• 34. Brown DM, Nguyen QD, Marcus DM; RIDE and RISE Research Group. Long-term Outcomes of Ranibizumab Therapy for Diabetic Macular Edema. The 36-Month Results from Two Phase III Trials: RISE and RIDE. Ophthalmology 2013. DOI: 2013.02.034.
• 35. Do DV, Nguyen QD, Boyer D, et al; DA VINCI Study Group. One-year outcomes of the DA VINCI Study of VEGF Trap-Eye in eyes with diabetic macular edema. Ophthalmology 2012; 119(8): 1658-1665.
• 36. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009; 116(6): 1142-1150.
• 37. Elman M, Ayala A, Bressler N, et al. Intravitreal Ranibizumab for diabetic macular edema with prompt versus eferred laser treatment: 5-year randomized trial results. Ophthalmology 2015; 122: 375-381.
• 38. Mrugacz M, Krajewska M, Bryl A, et al. Evaluate the effectiveness of laser therapy in the treatment of diabetic maculopathy. Pol Merk Lek 2013; 34(204): 351-354.

• Document Type: article